Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (otvorí nové okno)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Zdroj‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Označenie‎: PubMed 29471514

Identifikátor digitálneho objektu‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (otvorí nové okno)

High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution. (otvorí nové okno)

Azzarà A, Carulli G, Galimberti S, Baratè C, Fazzi R, Cervetti G, Petrini M.

Zdroj‎: Am J Hematol 2011;86(9):762-7.

Označenie‎: PubMed 21850658

Identifikátor digitálneho objektu‎: 10.1002/ajh.22111

https://www.ncbi.nlm.nih.gov/pubmed/21850658 (otvorí nové okno)

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (otvorí nové okno)

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

Zdroj‎: Acta Haematol 2007;117(3):162-7.

Označenie‎: PubMed 17148935

Identifikátor digitálneho objektu‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 (otvorí nové okno)

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (otvorí nové okno)

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Zdroj‎: Am J Hematol 2013;88(12):990-6.

Označenie‎: PubMed 23873823

Identifikátor digitálneho objektu‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 (otvorí nové okno)

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (otvorí nové okno)

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

Zdroj‎: J Clin Oncol 2011;29(28):3791-7.

Označenie‎: PubMed 21860000

Identifikátor digitálneho objektu‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 (otvorí nové okno)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (otvorí nové okno)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Zdroj‎: Cancer 2012;118(3):848-55.

Označenie‎: PubMed 21751205

Identifikátor digitálneho objektu‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (otvorí nové okno)

Management of anemia in cancer patients. (otvorí nové okno)

Calabrich A, Katz A.

Zdroj‎: Future Oncol 2011;7(4):507-17.

Označenie‎: PubMed 21463140

Identifikátor digitálneho objektu‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 (otvorí nové okno)

Leczenie ostrej białaczki u Świadków Jehowy—opis przypadku i przegląd piśmiennictwa. [Treatment of acute leukemia in Jehovah's Witnesses—a case report and review of the literature.] [Polish, English abstract] (otvorí nové okno)

Chojnowski K, Trelinski J.

Zdroj‎: Acta Haematol Pol 2007;38(4):479-84.

Označenie‎: EMBASE 2008089811

https://web.archive.org/web/20210506152723/https:/pthit.pl/Acta_Haematologica_Polonica,Ostra_bialaczka_Chemioterapia_Swiadkowie_Jehowy_Przetoczenie_krwi,395.html (otvorí nové okno)

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (otvorí nové okno)

Deger M, Eisterer W, Kutikova L, Salek S.

Zdroj‎: Support Care Cancer 2013;21(2):485-93.

Označenie‎: PubMed 22825456

Identifikátor digitálneho objektu‎: 10.1007/s00520-012-1538-0

https://www.ncbi.nlm.nih.gov/pubmed/22825456 (otvorí nové okno)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (otvorí nové okno)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Zdroj‎: BJU Int 2011;108(10):1582-7.

Označenie‎: PubMed 21443653

Identifikátor digitálneho objektu‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (otvorí nové okno)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (otvorí nové okno)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Zdroj‎: J Clin Oncol 2010;28(13):2239-45.

Označenie‎: PubMed 20368566

Identifikátor digitálneho objektu‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (otvorí nové okno)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (otvorí nové okno)

Ford PA, Grant SJ, Mick R, Keck G.

Zdroj‎: J Clin Oncol 2015;33(15):1674-9.

Označenie‎: PubMed 25870085

Identifikátor digitálneho objektu‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (otvorí nové okno)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (otvorí nové okno)

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Zdroj‎: Br J Cancer 2011;105(9):1267-72.

Označenie‎: PubMed 21959870

Identifikátor digitálneho objektu‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 (otvorí nové okno)

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (otvorí nové okno)

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

Zdroj‎: J Intern Med 2017;281(3):284-99.

Označenie‎: PubMed 27926979

Identifikátor digitálneho objektu‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 (otvorí nové okno)

How I treat cancer-associated anemia. (otvorí nové okno)

Gilreath JA, Rodgers GM

Zdroj‎: Blood 2020;136(7):801-13.

Označenie‎: PubMed 32556170

Identifikátor digitálneho objektu‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (otvorí nové okno)

Update on safety of ESAs in cancer-induced anemia. (otvorí nové okno)

Glaspy J.

Zdroj‎: J Natl Compr Canc Netw 2012;10(5):659-66.

Označenie‎: PubMed 22570294

https://www.ncbi.nlm.nih.gov/pubmed/22570294 (otvorí nové okno)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (otvorí nové okno)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Zdroj‎: Eur J Haematol. 2023 110(4):354-61.

Označenie‎: PubMed 36480004

Identifikátor digitálneho objektu‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (otvorí nové okno)

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. (otvorí nové okno)

Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K.

Zdroj‎: Int J Hematol 2015;102(4):401-12.

Označenie‎: PubMed 26323997

Identifikátor digitálneho objektu‎: 10.1007/s12185-015-1862-5

https://www.ncbi.nlm.nih.gov/pubmed/26323997 (otvorí nové okno)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (otvorí nové okno)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Zdroj‎: Cancer 2013;119(1):107-14.

Označenie‎: PubMed 22744794

Identifikátor digitálneho objektu‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (otvorí nové okno)

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (otvorí nové okno)

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

Zdroj‎: J Natl Cancer Inst 2013;105(14):1018-26.

Označenie‎: PubMed 23860204

Identifikátor digitálneho objektu‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 (otvorí nové okno)

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (otvorí nové okno)

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Zdroj‎: Cancer Sci 2013;104(4):481-5.

Označenie‎: PubMed 23331490

Identifikátor digitálneho objektu‎: 10.1111/cas.12105

https://www.ncbi.nlm.nih.gov/pubmed/23331490 (otvorí nové okno)

Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. (otvorí nové okno)

Park S, Greenberg P, Yucel A, Farmer C, O'Neill F, De Oliveira Brandao C, Fenaux P

Zdroj‎: Br J Haematol 2019;184(2):134-60.

Označenie‎: PubMed 30549002

Identifikátor digitálneho objektu‎: 10.1111/bjh.15707

https://www.ncbi.nlm.nih.gov/pubmed/30549002 (otvorí nové okno)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (otvorí nové okno)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Zdroj‎: Support Care Cancer 2012;20(1):159-65.

Označenie‎: PubMed 21359879

Identifikátor digitálneho objektu‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (otvorí nové okno)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (otvorí nové okno)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Zdroj‎: Leuk Lymphoma. 2019;60(9):2324-7.

Označenie‎: PubMed 30773115

Identifikátor digitálneho objektu‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (otvorí nové okno)

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (otvorí nové okno)

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

Zdroj‎: Oncologist 2010;15(9):935-43.

Označenie‎: PubMed 20798194

Identifikátor digitálneho objektu‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 (otvorí nové okno)

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (otvorí nové okno)

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Zdroj‎: Lung Cancer 2012;76(3):478-85.

Označenie‎: PubMed 22277104

Identifikátor digitálneho objektu‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 (otvorí nové okno)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (otvorí nové okno)

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Zdroj‎: Eur J Haematol 2016;97(1):33-8.

Označenie‎: PubMed 26341961

Identifikátor digitálneho objektu‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 (otvorí nové okno)

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (otvorí nové okno)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Zdroj‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Označenie‎: PubMed 29471514

Identifikátor digitálneho objektu‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (otvorí nové okno)

Intravenous iron in oncology. (otvorí nové okno)

Auerbach M, Ballard H.

Zdroj‎: J Natl Compr Canc Netw 2008;6(6):585-92.

Označenie‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 (otvorí nové okno)

Intravenous iron supplementation for the treatment of chemotherapy-induced anemia: a systematic review and meta-analysis of randomized controlled trials. (otvorí nové okno)

Buchrits S, Itzhaki O, Avni T, Raanani P, Gafter-Gvili A

Zdroj‎: J Clin Med. 2022;11(14):4156.

Označenie‎: PubMed 35887920

Identifikátor digitálneho objektu‎: 10.3390/jcm11144156

https://pubmed.ncbi.nlm.nih.gov/35887920/ (otvorí nové okno)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (otvorí nové okno)

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

Zdroj‎: Int J Colorectal Dis 2016;31(3):543-51.

Označenie‎: PubMed 26694926

Identifikátor digitálneho objektu‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 (otvorí nové okno)

How I treat cancer-associated anemia. (otvorí nové okno)

Gilreath JA, Rodgers GM

Zdroj‎: Blood 2020;136(7):801-13.

Označenie‎: PubMed 32556170

Identifikátor digitálneho objektu‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (otvorí nové okno)

Total dose iron dextran infusion in cancer patients: is it SaFe2+? (otvorí nové okno)

Gilreath JA, Stenehjem DD, Rodgers GM.

Zdroj‎: J Natl Compr Canc Netw 2012;10(5):669-76.

Označenie‎: PubMed 22570295

https://www.ncbi.nlm.nih.gov/pubmed/22570295 (otvorí nové okno)

Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. (otvorí nové okno)

Henry DH, Dahl NV, Auerbach MA.

Zdroj‎: Am J Hematol 2012;87(3):308-10.

Označenie‎: PubMed 22262486

Identifikátor digitálneho objektu‎: 10.1002/ajh.22262

https://www.ncbi.nlm.nih.gov/pubmed/22262486 (otvorí nové okno)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (otvorí nové okno)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Zdroj‎: Eur J Haematol. 2023 110(4):354-61.

Označenie‎: PubMed 36480004

Identifikátor digitálneho objektu‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (otvorí nové okno)

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (otvorí nové okno)

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

Zdroj‎: Curr Oncol. 2023 24;30(9):7836-51.

Označenie‎: PubMed 37754484

Identifikátor digitálneho objektu‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ (otvorí nové okno)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (otvorí nové okno)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Zdroj‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Označenie‎: PubMed 26845108

Identifikátor digitálneho objektu‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (otvorí nové okno)

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (otvorí nové okno)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

Zdroj‎: World J Gastroenterol 2014;20(8):1972-85.

Označenie‎: PubMed 24587673

Identifikátor digitálneho objektu‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 (otvorí nové okno)

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (otvorí nové okno)

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

Zdroj‎: South Asian J Cancer. 2023 15;12(2):93-9.

Označenie‎: PubMed 37969669

Identifikátor digitálneho objektu‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ (otvorí nové okno)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (otvorí nové okno)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Zdroj‎: J Clin Oncol 2008;26(10):1619-25.

Označenie‎: PubMed 18375891

Identifikátor digitálneho objektu‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (otvorí nové okno)

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (otvorí nové okno)

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

Zdroj‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

Označenie‎: PubMed 21972052

Identifikátor digitálneho objektu‎: 10.1007/s00432-011-1072-3

https://www.ncbi.nlm.nih.gov/pubmed/21972052 (otvorí nové okno)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (otvorí nové okno)

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

Zdroj‎: Ann Oncol 2013;24(2):475-82.

Označenie‎: PubMed 23071262

Identifikátor digitálneho objektu‎: 10.1093/annonc/mds338

https://www.ncbi.nlm.nih.gov/pubmed/23071262 (otvorí nové okno)

Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions. (otvorí nové okno)

Van Doren L, Steinheiser M, Boykin K, Taylor KJ, Menendez M, Auerbach M

Zdroj‎: Am J Hematol 2024;99(7):1338-48.

Označenie‎: PubMed 38282557

Identifikátor digitálneho objektu‎: 10.1002/ajh.27220

https://pubmed.ncbi.nlm.nih.gov/38282557/ (otvorí nové okno)